MPT Medical Properties Trust (MPT) Insider Trading, Ownership & Congress Trades
Real Estate · Real estate investment trusts · CIK 0001287865
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
229
13F, latest reported quarter
What the filings say about MPT
Insiders, 180 days
+$9.5K net bought
1 buyer
Medical Properties Trust insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, MEDICAL PROPERTIES TRUST INC insiders bought a net $9.5K of stock across 1 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.4% of the 542,504 shares held after it.
- No other insider bought within 30 days.
- 229 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior VP, Controller & CAO Hanna James Kevin bought about $9.5K of MPT on Aug 20, 2026, the largest insider purchase at the company on our record; 229 funds added in the latest 13F quarter.1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$9.5K over 180 days
+$9.5K over 90 days
more than 61% of Real Estate
Congress
no House purchase disclosed in the last 12 months
Funds
229 funds bought in last quarter
more than 76% of Real Estate
Revenue
-2.4% year over year
below 73% of Real Estate
Margin
-28.5% net margin
below 84% of Real Estate
Buybacks
$23.4M repurchased, FY to 2025-12-31
more than 58% of Real Estate
Short interest
29.8% of the float short (float per yahoo 2026-10-26) · 11.8 days to cover · settled 2026-09-30
the highest in Real Estate
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch MPT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-43.7%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MPT: institutional holders (13F)
13F holdings, latest reported quarter
75,253,906 sh
$347.7M
43,755,548 sh
$202.2M
25,162,287 sh
$118.5M
21,742,204 sh
$100.4M
17,637,883 sh
$81.1M
Congress trades in MPT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MPT planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
MPT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Dynamic U.S. Dividend Advantage ETF
$811.6K position · as of 2026-05-31
0.9%
Invesco S&P SmallCap Financials ETF
$151.6K position · as of 2026-05-31
0.6%
PIMCO RAE US Small Fund
$21.7M position · as of 2026-06-30
0.6%
DWS Core Equity VIP
$561.6K position · as of 2026-06-30
0.5%
DWS Core Equity Fund
$23.2M position · as of 2026-06-30
0.5%
iShares Residential and Multisector Real Estate ETF
$4.1M position · as of 2026-06-30
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$15.9M
$16.6M
$3.4M
-62%
+64%
2024
$16.4M
$17.1M
$3.0M
-72%
+20%
2023
$17.9M
$1.2M
$6.2M
-68%
-7%
2022
$16.0M
-$8.7M
$6.2M
-36%
-18%
2021
$17.0M
$33.7M
$7.1M
+25%
+5%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $9.5K bought by insiders over 180 days, 229 funds added last quarter. Each figure is a federal filing, dated the day it went public.
MPT financials
Revenue growth
-2.4%
XBRL, annual
Net margin
-28.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.0B
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM MPT
| FY Dec 2025 | $972.0M |
| FY Dec 2024 | $995.5M |
| FY Dec 2023 | $871.8M |
| FY Dec 2022 | $1.5B |
| FY Dec 2021 | $1.5B |
| Mar 2026 | $252.1M |
| Dec 2025 | $270.3M |
| Sep 2025 | $237.5M |
| Jun 2025 | $240.4M |
| Mar 2025 | $223.8M |
| Dec 2024 | $231.8M |
| Sep 2024 | $225.8M |
| Jun 2024 | $266.6M |
At each fiscal year end
Single quarter
Net margin, TTM
-12.6%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM MPT
| FY Dec 2025 | -28.5% |
| FY Dec 2024 | -242.1% |
| FY Dec 2023 | -63.8% |
| FY Dec 2022 | +58.5% |
| FY Dec 2021 | +42.5% |
| Mar 2026 | +13.0% |
| Dec 2025 | +6.4% |
| Sep 2025 | -32.7% |
| Jun 2025 | -40.9% |
| Mar 2025 | -52.8% |
| Dec 2024 | -178.1% |
| Sep 2024 | -354.8% |
| Jun 2024 | -120.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM MPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
2.13x
long-term debt only, 2026-03-31; equity 2026-03-31
Debt to equity MPT
| FY Dec 2025 | 2.11x |
| FY Dec 2024 | 1.83x |
| FY Dec 2023 | 1.32x |
| FY Dec 2022 | 1.19x |
| FY Dec 2021 | 1.34x |
| Mar 2026 | 2.13x |
| Dec 2025 | 2.11x |
| Sep 2025 | 2.06x |
| Jun 2025 | 2.00x |
| Mar 2025 | 1.99x |
| Dec 2024 | 1.83x |
| Sep 2024 | 1.69x |
| Jun 2024 | 1.51x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.02x
TTM operating cash flow over long-term debt only, 2026-03-31
Cash flow to debt MPT
| FY Dec 2025 | 0.02x |
| FY Dec 2024 | 0.03x |
| FY Dec 2023 | 0.05x |
| FY Dec 2022 | 0.07x |
| FY Dec 2021 | 0.07x |
| Mar 2026 | 0.02x |
| Dec 2025 | 0.02x |
| Sep 2025 | 0.02x |
| Jun 2025 | 0.02x |
| Mar 2025 | 0.02x |
| Dec 2024 | 0.03x |
| Sep 2024 | 0.03x |
| Jun 2024 | 0.04x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-2.7%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity MPT
| FY Dec 2025 | -5.9% |
| FY Dec 2024 | -38.7% |
| FY Dec 2023 | -6.9% |
| FY Dec 2022 | +10.6% |
| FY Dec 2021 | +8.3% |
| Mar 2026 | -2.7% |
| Dec 2025 | -5.9% |
| Sep 2025 | -14.0% |
| Jun 2025 | -26.0% |
| Mar 2025 | -28.8% |
| Dec 2024 | -38.7% |
| Sep 2024 | -38.8% |
| Jun 2024 | -24.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-0.9%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets MPT
| FY Dec 2025 | -1.9% |
| FY Dec 2024 | -14.8% |
| FY Dec 2023 | -2.9% |
| FY Dec 2022 | +4.5% |
| FY Dec 2021 | +3.5% |
| Mar 2026 | -0.9% |
| Dec 2025 | -1.9% |
| Sep 2025 | -4.7% |
| Jun 2025 | -9.1% |
| Mar 2025 | -10.3% |
| Dec 2024 | -14.8% |
| Sep 2024 | -15.5% |
| Jun 2024 | -9.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital MPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +2.3% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
assets or current liabilities not filed
Return on capital employed MPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing MPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 7.43x |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$10.9B
market value at close 2026-10-23 on 2026-05-06 shares, plus long-term debt only, 2026-03-31, minus cash 2026-03-31
Enterprise value MPT
| FY Dec 2025 | $12.2B |
| FY Dec 2024 | $10.9B |
| FY Dec 2023 | $12.8B |
| FY Dec 2022 | $16.7B |
| FY Dec 2021 | $24.9B |
| Mar 2026 | $12.0B |
| Dec 2025 | $12.2B |
| Sep 2025 | $12.3B |
| Jun 2025 | $11.7B |
| Mar 2025 | $12.4B |
| Dec 2024 | $10.9B |
| Sep 2024 | $12.5B |
| Jun 2024 | $11.3B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield MPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing MPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $972.0M | $995.5M | $871.8M | $1.5B |
| Net income | -$277.0M | -$2.4B | -$556.5M | $902.6M |
| EPS (diluted) | -0.46 | -4.02 | -0.93 | 1.50 |
| Operating cash flow | $230.8M | $245.5M | $505.8M | $739.0M |
| Cash | $540.9M | $332.3M | $250.0M | $235.7M |
| Long-term debt | $9.7B | $8.8B | $10.1B | $10.3B |
| Buybacks | $23.4M | n/a | n/a | $17.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
MPT Stock Sonar score 6/7 axes
Find similar shapesCompareMPT ranks highest on institutional and government (57th percentile) and insider conviction (55th), and lowest on risk and compliance (13th), among Real Estate peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MPT filings, in plain words
Are Medical Properties Trust insiders buying or selling MPT?
In the 180 days to 2026-10-28, Medical Properties Trust insiders were net buyers, a net $9.5K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Medical Properties Trust insiders were net buyers of MPT, a net $9.5K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
